dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.creator | Silva, H. T. | |
dc.creator | Felipe, C. R. | |
dc.creator | Machado, PGP | |
dc.creator | Garcia, R. | |
dc.creator | Motegi, S. | |
dc.creator | Hosaka, B. H. | |
dc.creator | Hanzawa, N. M. | |
dc.creator | Park, S. I. | |
dc.creator | Casarini, D. | |
dc.creator | Lima, V. C. | |
dc.creator | Franco, M. | |
dc.creator | Medina-Pestana, J. O. | |
dc.date.accessioned | 2016-01-24T12:33:49Z | |
dc.date.accessioned | 2022-10-07T20:46:50Z | |
dc.date.available | 2016-01-24T12:33:49Z | |
dc.date.available | 2022-10-07T20:46:50Z | |
dc.date.created | 2016-01-24T12:33:49Z | |
dc.date.issued | 2003-05-01 | |
dc.identifier | Transplantation Proceedings. New York: Elsevier B.V., v. 35, n. 3A, p. 177S-180S, 2003. | |
dc.identifier | 0041-1345 | |
dc.identifier | http://repositorio.unifesp.br/handle/11600/27231 | |
dc.identifier | 10.1016/S0041-1345(03)00232-X | |
dc.identifier | WOS:000182991100035 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/4022746 | |
dc.description.abstract | We show the key results of our 4-year experience with sirolimus in kidney transplant patients and in nontransplanted patients undergoing coronary angioplasty.Methods: Recipients of one-haplotype living-related kidney allografts were randomized to receive sirolimus (2 mg/d, n = 35) or azathioprine (2 mg/kg per day, n = 35). Recipients of fully mismatched living kidney allografts (n = 55) received sirolimus (2 mg/day). High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL. All kidney transplant patients received cyclosporine and prednisone. Sirolimus/cyclosporine pharmacokinetic studies were performed in 40 patients receiving 2 mg (n = 20) or 5 mg (n = 20) of sirolimus 7 days after transplantation. in the coronary intervention study, 12 patients at high risk for in-stent restenosis received sirolimus for 28 days after angioplasty.Results: the incidence of biopsy-confirmed acute rejection was 11.4% in recipients of one-haplotype. living-related kidney allografts, 16.4% in recipients of fully mismatched living kidney allografts, and 15% (8 to 12 ng/mL) and 4% (15 to 20 ng/mL) in high-risk recipients of black ethnicity. Cyclosporine exposure was higher after morning administration compared to evening administration. There were poor correlations between sirolimus and cyclosporine exposures. the 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30. the follow-up 3D-intravascular ultrasound restudy showed an in-stent relative volumetric obstruction of 9.9 +/- 5.5%. Sirolimus in highly effective in preventing kidney allograft acute rejection and in-stent coronary restenosis. | |
dc.language | eng | |
dc.publisher | Elsevier B.V. | |
dc.relation | Transplantation Proceedings | |
dc.rights | http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy | |
dc.rights | Acesso restrito | |
dc.title | Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty | |
dc.type | Artigo | |